Key result
Estrogen replacement therapy in postmenopausal women with CAD was associated with significantly lower levels of circulating cellular adhesion molecules compared to those not receiving ERT.
Why the study?
Does estrogen replacement therapy reduce circulating cellular adhesion molecules in postmenopausal women with coronary artery disease?
Cross-Sectional
Does estrogen replacement therapy reduce circulating cellular adhesion molecules in postmenopausal women with coronary artery disease?
Estrogen replacement therapy in postmenopausal women with CAD is associated with lower levels of circulating cellular adhesion molecules, suggesting a potential mechanism for estrogen's cardioprotective effects via reduced endothelial inflammation.
No takes yet. Share an insight, caveat, or question.
E2-cCAM associations in CAD should not yet change practice; leaves open causal role of estrogen in endothelial inflammation.
Caulin‐Glaser et al. (1998) conducted a cross-sectional in Coronary artery disease. Estrogen replacement therapy (ERT) vs. No ERT (men with CAD, postmenopausal women with CAD not receiving ERT) was evaluated on Levels of circulating cellular adhesion molecules (E-selectin, VCAM-1, ICAM-1). Estrogen replacement therapy in postmenopausal women with CAD was associated with significantly lower levels of circulating cellular adhesion molecules compared to those not receiving ERT.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: